Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Eton announced fiscal Q2 2026 results for the quarter ended June 30, 2026.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Eton announced fiscal Q2 2026 results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
- Adjusted EBITDA featured as management’s primary non-GAAP performance metric
- Investors should reconcile Adjusted EBITDA with U.S. GAAP results before assessing profitability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $37.6M, up 99% YoY, signaling rapid commercial scaling led by HEMANGEOL and portfolio-wide growth
- GAAP diluted EPS $0.35, Adjusted EBITDA $16.2M, with margin expanding to 43% from 16%
- 2026 guidance raised to revenue above $145M and Adjusted EBITDA margin at least 35%, versus prior thresholds of $120M and 30%
- Growth investments add near-term cost risk: $3M ASN-001 licensing expense and potential $4M ALKINDI SPRINKLE milestone
- ASN-001 targets potential H2 2027 NDA submission, while KHINDIVI label expansion could support approval in H1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.